Prostate Cancer 

Last Updated:

Focused ultrasound treatment for the prostate is available in the United States.

Three focused ultrasound systems for destroying diseased prostate tissue are approved by the Food and Drug Administration. In addition, Medicare has taken initial steps to cover this treatment, which will hopefully impact the commercial carriers to do the same.

Focused Ultrasound Therapy

Focused ultrasound is a noninvasive, radiation-free method to destroy prostate tissue and treat prostate disease. Using real-time image guidance, the physician directs a focused beam of ultrasound energy to a selected volume in the patient’s prostate gland.

How it Works
Focused ultrasound energy heats and destroys the targeted tissue at the focal point within seconds. This process is repeated until the entire selected volume or the entire gland is destroyed.

The primary options for treatment of prostate cancer include the avoidance of invasive procedures that may include ionizing radiation and surgery.

Focused ultrasound is a low-morbidity treatment that usually only requires a single therapy session and has a short recovery time. It is reported to have a low complication rate, especially when considering post-procedure impotence and incontinence. Focused ultrasound treatment does not use ionizing radiation, and it is possible to offer it as a salvage therapy for patients who fail radiation treatment. Focused ultrasound treatment can be a complement to drug therapy, enabling enhanced delivery of chemotherapy or immunotherapy to tumors, and it may potentially induce an anti-tumor immune response.

Clinical Trials

A registry for the TULSA-PRO is tracking patient outcomes for this device.

A clinical trial in Norway is comparing HIFU to active surveillance.

A clinical trial in the US is a randomized trial comparing the TULSA PRO to radical prostatectomy.

See a full list of prostate cancer clinical trials > 

See a list of treatment sites >
See a list of clinical trials sites >
See a list of laboratory research sites >

Regulatory Approval and Reimbursement

Focused ultrasound devices have been cleared to treat the prostate in approximately 50 countries, including the United States. Several systems for focused ultrasound ablation of prostate tissue are available in various geographical regions, each differing in their guidance method (ultrasound vs. magnetic resonance imaging) and approach – transrectal or transurethral.

While the Foundation attempts to keep the list of sites complete, there have been many purchases of the focused ultrasound systems. For the latest information on availability, we recommend contacting the manufacturers’ directly or using their online search functions. 

There are four focused ultrasound manufacturers that are approved in the US for the ablation (destruction) of prostate tissue – Sonablate Corp.,  EDAP-TMSProfound Medical, and Insightec. Sonablate and EDAP deliver care outside of the MRI facility, so they are found in surgery centers and surgical suites, as well as in hospitals. 

There are additional sites that use mobile focused ultrasound equipment. These sites may not be listed on the EDAP, Sonablate, or Profound Medical sites, and the best way to find them is to contact local urologists to see if they have focused ultrasound capability.

Reimbursement for primary treatment in the US has been lagging, and Medicare and most insurance companies are either covering a portion of the expense or not covering it at all. In the specific instance of salvage therapy after failed radiation, some Medicare providers and commercial insurance carriers are covering focused ultrasound use in this setting. As always, it is best to check with your specific carrier.

Notable Papers 

Suggested Reading: Focused Ultrasound for Prostate Cancer Case Study (2021)

Khandwala YS, Soerensen SJC, Morisetty S, Ghanouni P, Fan RE, Vesal S, Rusu M, Sonn GA. The Association of Tissue Change and Treatment Success During High-intensity Focused Ultrasound Focal Therapy for Prostate Cancer. Eur Urol Focus. 2023 Jul;9(4):584-591. doi: 10.1016/j.euf.2022.10.010. Epub 2022 Nov 10. PMID: 36372735 

Henderson RH, Bryant C, Nichols RC Jr, Mendenhall WM, Mendenhall NP. Local salvage of radiorecurrent prostate cancer. Prostate. 2023 Aug;83(11):1001-1010. doi: 10.1002/pros.24551. Epub 2023 May 7. PMID: 37150849 

Rosnitskiy PB, Tsysar SA, Karzova MM, Buravkov SV, Malkov PG, Danilova NV, Ponomarchuk EM, Sapozhnikov OA, Khokhlova TD, Schade GR, Maxwell AD, Wang YN, Kadrev AV, Chernyaev AL, Okhobotov DA, Kamalov AA, Khokhlova VA. Pilot ex vivo study on non-thermal ablation of human prostate adenocarcinoma tissue using boiling histotripsy. Ultrasonics. 2023 Aug;133:107029. doi: 10.1016/j.ultras.2023.107029. Epub 2023 May 7. PMID: 37207594 

Deivasigamani S, Kotamarti S, Rastinehad AR, Salas RS, de la Rosette JJMCH, Lepor H, Pinto P, Ahmed HU, Gill I, Klotz L, Taneja SS, Emberton M, Lawrentschuk N, Wysock J, Feller JF, Crouzet S, Kumar M P, Seguier D, Adams ES, Michael Z, Abreu A, Jack Tay K, Ward JF, Shinohara K, Katz AE, Villers A, Chin JL, Stricker PD, Baco E, Macek P, Ahmad AE, Chiu PKF, Crawford ED, Rogers CG, Futterer JJ, Rais-Bahrami S, Robertson CN, Hadaschik B, Marra G, Valerio M, Chong KT, Kasivisvanathan V, Tan WP, Lomas D, Walz J, Guimaraes GC, Mertziotis NI, Becher E, Finelli A, Kasraeian A, Lebastchi AH, Vora A, Rosen MA, Bakir B, Arcot R, Yee S, Netsch C, Meng X, de Reijke TM, Tan YG, Regusci S, Benjamin TGR, Olivares R, Noureldin M, Bianco FJ, Sivaraman A, Kim FJ, Given RW, Dason S, Sheetz TJ, Shoji S, Schulman A, Royce P, Shah TT, Scionti S, Salomon G, Laguna P, Tourinho-Barbosa R, Aminsharifi A, Cathelineau X, Gontero P, Stabile A, Grummet J, Ledbetter L, Graton M, Stephen Jones J, Polascik TJ, Polascik TJ. Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer: A Focal Therapy Society Best Practice Statement. Eur Urol. 2023 Jul 5:S0302-2838(23)02943-3. doi: 10.1016/j.eururo.2023.06.013. PMID: 37419773 

Parry MG, Sujenthiran A, Nossiter J, Morris M, Berry B, Nathan A, Aggarwal A, Payne H, van der Meulen J, Clarke NW. Prostate cancer outcomes following whole-gland and focal high-intensity focused ultrasound. BJU Int. 2023 Jul 8. doi: 10.1111/bju.16122. PMID: 37422679 

Mäkelä P, Anttinen M, Wright C, Sainio T, Boström PJ, Sequeiros RB. Evolution of non-perfused volume after transurethral ultrasound ablation of prostate: A retrospective 12-month analysis. Eur J Radiol Open. 2023 Jul 6;11:100506. doi: 10.1016/j.ejro.2023.100506. eCollection 2023 Dec. PMID: 37456928 

Nicoletti R, Alberti A, Castellani D, Yee CH, Zhang K, Poon DMC, Chiu PK, Campi R, Resta GR, Dibilio E, Pirola GM, Chiacchio G, Fuligni D, Brocca C, Giulioni C, De Stefano V, Serni S, Gauhar V, Ng CF, Gacci M, Teoh JYC. Oncological results and cancer control definition in focal therapy for Prostate Cancer: a systematic review. Prostate Cancer Prostatic Dis. 2023 Jul 28. doi: 10.1038/s41391-023-00699-7. PMID: 37507479 

Heard JR, Naser-Tavakolian A, Nazmifar M, Ahdoot M. Focal prostate cancer therapy in the era of multiparametric MRI: a review of options and outcomes. Prostate Cancer Prostatic Dis. 2023 Jun;26(2):218-227. doi: 10.1038/s41391-022-00501-0. Epub 2022 Mar 4. PMID: 35246609 

Ahn H, Hwang SI, Kim TM, Lee HJ, Choe G, Hong SK, Byun SS, Lee H. Diagnostic value of multiparametric MRI in detecting residual or recurrent prostate cancer after high-intensity focused ultrasound. Prostate Cancer Prostatic Dis. 2023 Jun;26(2):360-366. doi: 10.1038/s41391-022-00531-8. Epub 2022 May 28. PMID: 35643729 

Benidir T, Wood A, Lone Z, Schwen Z, Abouassaly R, Nguyen J, Olivares R, Weight CJ, Purysko AS. The Feasibility and Value of a Focal Therapy Multidisciplinary Tumor Board, Including Radiographic and Pathological Overreads in Refining the Selection for High Intensity Focused Ultrasound in Prostate Cancer Patients. Urol Pract. 2023 Jul;10(4):372-377. doi: 10.1097/UPJ.0000000000000400. Epub 2023 Mar 16. PMID: 37103528 

Pan Y, Wang S, Zhou H, Niu S, Liu X. Endoscopic Resection Improved High-Intensity Focused Ultrasound Ablation Outcomes for Prostate Cancer: A Meta-Analysis of Comparative Studies. Urol J. 2023 Jun 18. doi: 10.22037/uj.v20i.7378. PMID: 37330689 

Topoozian M, Calais J, Felker E, Sisk A, Gonzalez S, Lee SJ, Marks LS. Focal therapy of prostate cancer: Assessment with prostate-specific membrane antigen (PSMA) imaging. Urol Case Rep. 2023 Jun 9;50:102461. doi: 10.1016/j.eucr.2023.102461. eCollection 2023 Sep. PMID: 37358989 

Light A, Peters M, Reddy D, Kanthabalan A, Otieno M, Pavlou M, Omar R, Adeleke S, Giganti F, Brew-Graves C, Williams NR, Emara A, Haroon A, Latifoltojar A, Sidhu H, Freeman A, Orczyk C, Nikapota A, Dudderidge T, Hindley RG, Virdi J, Arya M, Payne H, Mitra AV, Bomanji J, Winkler M, Horan G, Moore C, Emberton M, Punwani S, Ahmed HU, Shah TT. External validation of a risk model predicting failure of salvage focal ablation for prostate cancer. BJU Int. 2023 Jun 29. doi: 10.1111/bju.16102. PMID: 37385981 

Duwe G, Boehm K, Haack M, Sparwasser P, Brandt MP, Mager R, Tsaur I, Haferkamp A, Höfner T. Single-center, prospective phase 2 trial of high-intensity focused ultrasound (HIFU) in patients with unilateral localized prostate cancer: good functional results but oncologically not as safe as expected. World J Urol. 2023 May;41(5):1293-1299. doi: 10.1007/s00345-023-04352-9. Epub 2023 Mar 15. PMID: 36920492 

Chen X, Cvetkovic D, Chen L, Ma CM. An in-vivo study of the combined therapeutic effects of pulsed non-thermal focused ultrasound and radiation for prostate cancer. Int J Radiat Biol. 2023 May 19:1-8. doi: 10.1080/09553002.2023.2214204. PMID: 37191462 

Giganti F, Dickinson L, Orczyk C, Haider A, Freeman A, Emberton M, Allen C, Moore CM. Prostate Imaging after Focal Ablation (PI-FAB): A Proposal for a Scoring System for Multiparametric MRI of the Prostate After Focal Therapy. Eur Urol Oncol. 2023 May 18:S2588-9311(23)00083-4. doi: 10.1016/j.euo.2023.04.007. PMID: 37210343 

Ayerra Perez H, Barba Abad JF, Extramiana Cameno J. An Update on Focal Therapy for Prostate Cancer. Clin Genitourin Cancer. 2023 May 3:S1558-7673(23)00101-5. doi: 10.1016/j.clgc.2023.04.013. PMID: 37258359 

Duan H, Ghanouni P, Daniel B, Rosenberg J, Davidzon GA, Aparici CM, Kunder C, Sonn GA, Iagaru A. A Pilot Study of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High-Intensity Focused Ultrasound Therapy. J Nucl Med. 2023 Apr;64(4):592-597. doi: 10.2967/jnumed.122.264783. Epub 2022 Nov 3.

Sonn G, Khandwala Y. Reply to Carmen Gravina, Riccardo Lombardo, and Cosimo De Nunzio’s Letter to the Editor re: Yash S. Khandwala, Simon John Christoph Soerensen, Shravan Morisetty, et al. The Association of Tissue Change and Treatment Success During High-intensity Focused Ultrasound Focal Therapy for Prostate Cancer. Eur Urol Focus. In press. Eur Urol Focus. 2023 Apr 1:S2405-4569(23)00087-1. doi: 10.1016/j.euf.2023.03.019.

Habashy D, Reddy D, Peters M, Shah TT, van Son M, van Rossum P, Tanaka MB, Cullen E, Engle R, McCracken S, Greene D, Hindley RG, Emara A, Nigam R, Orczyk C, Shergill I, Persad R, Virdi J, Moore CM, Arya M, Winkler M, Emberton M, Ahmed HU, Dudderidge T. Evaluation of Outcomes Following Focal Ablative Therapy for Treatment of Localized Clinically Significant Prostate Cancer in Patients >70 Years: A Multi-institute, Multi-energy 15-Year Experience. J Urol. 2023 Apr 4:101097JU0000000000003443. doi: 10.1097/JU.0000000000003443.

Meyer L, Bohlscheid A, Lemmer O, van de Plas J, Leboutte F, Hadaschik BA, Neisius A, Willinek WA. MR-Guided Transurethral Ultrasound Ablation of Prostate Cancer: Initial Experience of Monitoring Tumor Response by Dynamic Apparent Diffusion Coefficient Measurements at 3.0 T. Urol Int. 2023 Apr 18:1-9. doi: 10.1159/000529873.

Ghoreifi A, Kaneko M, Peretsman S, Iwata A, Brooks J, Shakir A, Sugano D, Cai J, Cacciamani G, Park D, Lebastchi AH, Ukimura O, Bahn D, Gill I, Abreu AL. Patient-reported Satisfaction and Regret Following Focal Therapy for Prostate Cancer: A Prospective Multicenter Evaluation. Eur Urol Open Sci. 2023 Feb 18;50:10-16. doi: 10.1016/j.euros.2023.02.003. eCollection 2023 Apr.

Mäkelä P, Wright C, Anttinen M, Boström PJ, Blanco Sequeiros R. Safety and efficacy of MRI-guided transurethral ultrasound ablation for radiorecurrent prostate cancer in the presence of gold fiducial markers. Acta Radiol. 2023 Mar;64(3):1228-1237. doi: 10.1177/02841851221108292. Epub 2022 Jun 24.

Ghai S, Perlis N. Beyond the AJR: MRI-Guided Focused Ultrasound Focal Therapy for Intermediate-Risk Prostate Cancer. AJR Am J Roentgenol. 2023 Apr;220(4):610. doi: 10.2214/AJR.22.28413. Epub 2022 Aug 24.

Westhoff N, Ernst R, Kowalewski KF, Derigs F, Neuberger M, Nörenberg D, Popovic ZV, Ritter M, Stephan Michel M, von Hardenberg J. Medium-term Oncological Efficacy and Patient-reported Outcomes After Focal High-intensity Focused Ultrasound: The FOXPRO Trial. Eur Urol Focus. 2023 Mar;9(2):283-290. doi: 10.1016/j.euf.2022.10.006. Epub 2022 Nov 4.

Duwe G, Boehm K, Haack M, Sparwasser P, Brandt MP, Mager R, Tsaur I, Haferkamp A, Höfner T. Single-center, prospective phase 2 trial of high-intensity focused ultrasound (HIFU) in patients with unilateral localized prostate cancer: good functional results but oncologically not as safe as expected. World J Urol. 2023 Mar 15. doi: 10.1007/s00345-023-04352-9.

Koelker M, Labban M, Frego N, Meyer CP, Salomon G, Lipsitz SR, Withington J, Moore CM, Tempany CM, Tuncali K, George A, Kibel AS, Trinh QD, Cole AP. Contemporary patterns of local ablative therapies for prostate cancer at United States cancer centers: results from a national registry. World J Urol. 2023 Mar 17. doi: 10.1007/s00345-023-04354-7.

Gravina C, Lombardo R, De Nunzio C. Re: Yash S. Khandwala, Simon John Christoph Soerensen, Shravan Morisetty, et al. The Association of Tissue Change and Treatment Success During High-intensity Focused Ultrasound Focal Therapy for Prostate Cancer. Eur Urol Focus. In press. Eur Urol Focus. 2023 Mar 31:S2405-4569(23)00088-3. doi: 10.1016/j.euf.2023.02.012.

Cribbs KA, Manning EF, Zhou J, Lahue BJ, Polascik TJ. Real-World Comparative Safety and Effectiveness of Irreversible Electroporation and High-Intensity Focused Ultrasound for Prostate Cancer Ablation. Urology. 2023 Feb 1:S0090-4295(23)00071-7. doi: 10.1016/j.urology.2023.01.024.

Zhang X, Greiser S, Roy U, Lange F, van Gorkum R, Fournelle M, Speicher D, Tretbar S, Melzer A, Landgraf L. Evaluation of a Developed MRI-Guided Focused Ultrasound System in 7 T Small Animal MRI and Proof-of-Concept in a Prostate Cancer Xenograft Model to Improve Radiation Therapy. Cells. 2023 Feb 2;12(3):481. doi: 10.3390/cells12030481.

Rabinowitz MJ, Haney NM, Myers AA, Dora CD, Pavlovich CP. Urinary Outcomes After Magnetic Resonance Imaging-Guided Whole-Gland Transurethral Ultrasound Ablation for Prostate Cancer: Comparison of Suprapubic Tube to Indwelling Urethral Catheter. J Endourol. 2023 Jan;37(1):1-7. doi: 10.1089/end.2022.0214. Epub 2022 Sep 26.

Dai J, Wu Y, Chen Z, Xiao L, Zhang W, Cao Y. Sonosensitive Phase-Changeable Nanoparticle Mediated Enhanced Chemotherapy in Prostate Cancer by Low-Intensity Focused Ultrasound. Int J Mol Sci. 2023 Jan 3;24(1):825. doi: 10.3390/ijms24010825.

Alabousi M, Ghai S. Magnetic resonance imaging-guided ultrasound ablation for prostate cancer – A contemporary review of performance. Front Oncol. 2023 Jan 4;12:1069518. doi: 10.3389/fonc.2022.1069518. eCollection 2022.

Wright C, Mäkelä P, Bigot A, Anttinen M, Boström PJ, Blanco Sequeiros R. Deep learning prediction of non-perfused volume without contrast agents during prostate ablation therapy. Biomed Eng Lett. 2022 Nov 8;13(1):31-40. doi: 10.1007/s13534-022-00250-y. eCollection 2023 Feb.

Dias N, Rodriguez-Sanchez L, Colandrea G, Macek P, Cathelineau X. Medium-term oncological outcomes of intermediate-risk prostate cancer treated with HIFU or cryotherapy. A single center 10-year experience. Arch Ital Urol Androl. 2022 Dec 27;94(4):413-419. doi: 10.4081/aiua.2022.4.413.

Marra G, Soeterik T, Oreggia D, Tourinho-Barbosa R, Moschini M, Stabile A, Filippini C, van Melick HH, van den Bergh RC, Gontero P, Pasquali C, Macek P, Cathala N, Sanchez-Salas R, Cathelineau X. Focal High-Intensity Focused Ultrasound vs. Active Surveillance for ISUP Grade 1 Prostate Cancer: Medium-Term Results of a Matched-Pair Comparison. Clin Genitourin Cancer. 2022 Dec;20(6):592-604. doi: 10.1016/j.clgc.2022.06.009. Epub 2022 Jun 30.

Nassiri N, Richardson S, Kuppermann D, Brisbane WG, Gonzalez S, Kwan L, Felker E, Wallner C, Marks LS. Partial Gland Ablation of Prostate Cancer: Effects of Repeat Treatment. Urology. 2022 Dec;170:161-167. doi: 10.1016/j.urology.2022.07.024. Epub 2022 Jul 28.

Hall WA, Shoag J, Spratt DE. Re: MRI-guided Focused Ultrasound Focal Therapy for Patients with Intermediate-risk Prostate Cancer: A Phase 2b, Multicentre Study. Eur Urol. 2022 Dec;82(6):661-662. doi: 10.1016/j.eururo.2022.08.027. Epub 2022 Sep 30.

Zhong J, Brown S, Serra M, Shuttleworth P, Bownes P, Thompson C, Reed R, Reeves K, Dubec M, McHugh D, Eccles C, Chuter R, Tsang YM, Taylor NJ, West C, Buckley D, Scarsbrook A, Choudhury A, Hoskin P, Henry A. Reirradiation Options for Previously Irradiated Prostate cancer (RO-PIP): Feasibility study investigating toxicity outcomes following reirradiation with stereotactic body radiotherapy (SBRT) versus high-dose-rate brachytherapy (HDR-BT). BMJ Open. 2022 Nov 8;12(11):e068580. doi: 10.1136/bmjopen-2022-068580.

Shoji S, Kuroda S, Uemura K, Oda K, Kano T, Ogawa T, Umemoto T, Nakano M, Kawakami M, Nitta M, Hasegawa M, Miyajima A. Risk Factors for Severe Erectile Dysfunction after Focal Therapy with High-Intensity Focused Ultrasound for Prostate Cancer. Biomedicines. 2022 Nov 10;10(11):2876. doi: 10.3390/biomedicines10112876.

Khandwala YS, Soerensen SJC, Morisetty S, Ghanouni P, Fan RE, Vesal S, Rusu M, Sonn GA. The Association of Tissue Change and Treatment Success During High-intensity Focused Ultrasound Focal Therapy for Prostate Cancer. Eur Urol Focus. 2022 Nov 10:S2405-4569(22)00237-1. doi: 10.1016/j.euf.2022.10.010.

Di Lalla V, Elakshar S, Anidjar M, Tolba M, Hassan T, Bahoric B, McPherson V, Probst S, Niazi T. Salvage external beam radiotherapy after HIFU failure in localized prostate cancer: A single institution experience. Front Oncol. 2022 Nov 3;12:1028858. doi: 10.3389/fonc.2022.1028858. eCollection 2022.

Khokhlova VA, Rosnitskiy PB, Tsysar SA, Buravkov SV, Ponomarchuk EM, Sapozhnikov OA, Karzova MM, Khokhlova TD, Maxwell AD, Wang YN, Kadrev AV, Chernyaev AL, Chernikov VP, Okhobotov DA, Kamalov AA, Schade GR. Initial Assessment of Boiling Histotripsy for Mechanical Ablation of Ex Vivo Human Prostate Tissue. Ultrasound Med Biol. 2022 Oct 4:S0301-5629(22)00507-5. doi: 10.1016/j.ultrasmedbio.2022.07.014.

Miura M, Takahashi S, Fukumoto M, Higashiyama H. Initial experience of transurethral ultrasound ablation of the prostate in Asia. BJUI Compass. 2022 Jun 23;3(6):405-407. doi: 10.1002/bco2.175. eCollection 2022 Nov.

DE Luca S, Checcucci E, Piramide F, Russo F, Alessio P, Garrou D, Peretti D, Sica M, Volpi G, Piana A, DE Cillis S, Amparore D, Manfredi M, Fiori C, Porpiglia F. MRI/real-time ultrasound image fusion guided high-intensity focused ultrasound (HIFU): a prospective comparative and functional analysis of different ablative techniques. Minerva Urol Nephrol. 2022 Oct 26. doi: 10.23736/S2724-6051.22.04853-4.

Pan Y, Wang S, Liu L, Liu X. Whole-gland high-intensity focused ultrasound ablation and transurethral resection of the prostate in the patients with prostate cancer: A systematic review and meta-analysis. Front Oncol. 2022 Oct 12;12:988490. doi: 10.3389/fonc.2022.988490. eCollection 2022.

Mesci A, Gouran-Savadkoohi M, Ribeiro D, Dayes I, Lukka H, Schnarr K, Quan K, Goldberg M, Hallock A, Tsakiridis T. Salvage radiotherapy following HiFU: An institutional series and literature review. J Med Imaging Radiat Oncol. 2022 Sep;66(6):847-852. doi: 10.1111/1754-9485.13384. Epub 2022 Feb 16.

Barham DW, Barnard J, Gelman J. Urethral Stricture/Stenosis as a Complication of High Intensity Focused Ultrasound of the Prostate (HIFU): What is the Overall Patient Experience? Urology. 2022 Sep;167:211-217. doi: 10.1016/j.urology.2022.04.041. Epub 2022 Jun 6.

Karwacki J, Kiełbik A, Szlasa W, Sauer N, Kowalczyk K, Krajewski W, Saczko J, Kulbacka J, Szydełko T, Małkiewicz B. Boosting the Immune Response-Combining Local and Immune Therapy for Prostate Cancer Treatment. Cells. 2022 Sep 7;11(18):2793. doi: 10.3390/cells11182793.

Rabinowitz MJ, Haney NM, Myers AA, Dora C, Pavlovich C. Urinary Outcomes after Magnetic Resonance Imaging-Guided Whole Gland Transurethral Ultrasound Ablation (TULSA) for Prostate Cancer: Comparison of Suprapubic Tube to Indwelling Urethral Catheter. J Endourol. 2022 Aug 26. doi: 10.1089/end.2022.0214.

Click here for additional references from PubMed.

Video courtesy of SonaCare Medical

FDA Approved
International Approval
Clinical Trials